Health has always been one of people’s demands for a high quality of
life. For thousands of years, both Chinese and Western medicine have
accumulated a lot of medical knowledge and ideas. However, due to the weakness
of China in the past century, Chinese medicine has become irrelevant.However, with the outbreak and persistence of COVID-19 and China’s
actions in the fight against the epidemic, people have further realized the
importance of health, and TCM has again entered people’s field of vision.
Taking Company Y as an example, this paper analyzes the listing feasibility of
Company Y from its macro environment, basic overview, advantages and
disadvantages in the industry, financial indicators, enterprise valuation and
other aspects. Then, based on the above analysis and combined with the
development trend and recent development goals of the enterprise, it concludes
that under the current macro and micro environment, Company Y can and should be
encouraged to list on the New Third Board, with a stock price of about 7 yuan
and a price-earnings ratio of about 25 times.
References
[1]
Li, C. (2018). Comparative Analysis of EVA Valuation Method and DCF Valuation Method. Beijing: University of International Business and Economics.
[2]
Li, Y. N. (2019). Study on the Applicability of Value Evaluation Methods for Listed Companies in Traditional Chinese Medicine Industry. Shanghai: Donghua University.
[3]
Luo, H. (2019). Feasibility Analysis and Countermeasure Study of FR Company Listed on New Third Board. Xi’an: Xidian University.
[4]
Shi, H. (2015). Research on Valuation of Listed Companies in Chinese Traditional Chinese Medicine Manufacturing Sector. Shanghai: Shanghai Jiao Tong University.
[5]
Wei, G. N. (2018). Feasibility Analysis of Dual Share System in China Based on SWOT Analysis: A Case Study of Jingdong’s Listing in the United States. Accounting for Township Enterprises in China, No. 10, 27-28.
[6]
Weng, Q. S. (2018). Analysis of the Listing Feasibility of Anhui City Pharmaceutical Co., Ltd. Based on Financial Indicators. Economic and Trade Practice, No. 16, 57+59.
[7]
Xia, M. L. (2020). Analysis on Financial Performance Evaluation of Yiling Pharmaceutical Company. Shanghai Commerce, No. 4, 58-59.
[8]
Yan, C. X. (2018). Research on the Proitability Model and Financial Evaluation of X Company. Shenyang: Shenyang University,.
[9]
Zhang, S. K., & Yuan, L. J. (2018). Research on the Feasibility of Listing of Enterprises Based on Financial Analysis: A Case Study of Anhui Airite. Public Investment Guide, No. 24, 220-221.
[10]
Zhu, X. J. (2017). Research on Financial Risks of Listed Companies in Traditional Chinese Medicine Industry. Chengdu: Southwest Jiaotong University.
